Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Gliclazide

Gliclazide: A Time-Tested Sulfonylurea in Type 2 Diabetes Management

Introduction

Diabetes mellitus, particularly type 2 diabetes mellitus (T2DM), is a chronic metabolic disorder characterized by insulin resistance and impaired insulin secretion. With an increasing global prevalence, effective and sustainable treatment options are vital. Among the widely used antidiabetic medications is Gliclazide, a second-generation sulfonylurea that has stood the test of time due to its potent glucose-lowering effects, safety profile, and cardiovascular neutrality.

Gliclazide

Gliclazide is an oral hypoglycemic agent belonging to the sulfonylurea class of drugs. It is primarily used for managing type 2 diabetes in patients whose blood glucose levels are not adequately controlled by diet, exercise, or monotherapy with other agents like metformin.

Basic Details:

  • Chemical class: Sulfonylurea (second-generation)

  • Available formulations: Immediate-release (IR) and modified-release (MR)

  • Common trade names: Diamicron®, Glyade®, Reclazide®

Mechanism of Action

Gliclazide works by stimulating the pancreatic beta cells to release insulin. It binds to the sulfonylurea receptor (SUR1) on the pancreatic beta cell membrane, closing the ATP-sensitive potassium (K-ATP) channels. This leads to membrane depolarization, opening of voltage-gated calcium channels, influx of calcium, and subsequent insulin secretion.

Additional Actions:

  • Improved insulin secretion in response to meals (glucose-dependent insulinotropic effect)

  • Antioxidant and anti-platelet effects, which may contribute to cardiovascular protection

  • Reduction in microvascular complications of diabetes (notably retinopathy and nephropathy)

Pharmacokinetics

Absorption:

  • Well absorbed orally

  • Peak plasma levels reached within 4–6 hours for IR and 6–12 hours for MR formulations

Metabolism:

  • Extensively metabolized in the liver

  • No active metabolites with hypoglycemic action

Elimination:

  • Excreted mainly in urine as inactive metabolites

Clinical Uses of Gliclazide

1. Type 2 Diabetes Mellitus

Gliclazide is approved for the treatment of non-insulin dependent diabetes in adults. It is typically used when:

  • Diet and exercise fail to maintain glycemic targets

  • Monotherapy with metformin or other agents is insufficient

  • Combination therapy is required to optimize blood glucose control

2. Combination Therapy

Gliclazide can be combined with:

  • Metformin

  • Thiazolidinediones

  • DPP-4 inhibitors

  • SGLT2 inhibitors

  • Insulin (in certain cases)

Dosage and Administration

Immediate-Release (IR):

  • Starting dose: 40–80 mg once or twice daily

  • Maximum dose: 320 mg/day (divided)

Modified-Release (MR):

  • Starting dose: 30 mg once daily with breakfast

  • Titrated based on glucose control

  • Maximum dose: 120 mg/day

Efficacy of Gliclazide

Gliclazide is effective in:

  • Reducing HbA1c by 1–2%

  • Lowering fasting plasma glucose (FPG) and postprandial glucose (PPG)

  • Maintaining long-term glycemic control

  • Decreasing the incidence of diabetic microvascular complications, particularly retinopathy and nephropathy (as shown in studies like ADVANCE)

ADVANCE Trial: Landmark Evidence

The ADVANCE trial (Action in Diabetes and Vascular disease: PreterAx and DiamicroN MR Controlled Evaluation) was a large, multicenter trial that assessed the long-term effects of intensive blood glucose control using Gliclazide MR in over 11,000 patients with T2DM.

Key Findings:

  • Reduction in major microvascular events (especially nephropathy)

  • Modest reduction in macrovascular events

  • No significant increase in hypoglycemia compared to standard control

  • Established Gliclazide MR as a cardiovascular-safe option

Advantages of Gliclazide over Other Sulfonylureas

Gliclazide has several clinical advantages that make it preferable to other sulfonylureas such as glibenclamide or glipizide:

1. Lower Risk of Hypoglycemia

Gliclazide has a more glucose-dependent action, minimizing the risk of severe hypoglycemia, especially in the elderly.

2. Cardiovascular Safety

Gliclazide has shown a neutral or even protective effect on cardiovascular outcomes, unlike some other sulfonylureas associated with higher risk.

3. Microvascular Protection

Demonstrated benefits in slowing the progression of diabetic complications such as nephropathy and retinopathy.

4. Better Tolerability

Fewer gastrointestinal and allergic side effects compared to first-generation sulfonylureas.

Side Effects and Safety Profile

While Gliclazide is generally well tolerated, it does have some potential adverse effects:

Common Side Effects:

  • Hypoglycemia, especially with irregular meals or in renal impairment

  • Weight gain (modest, compared to insulin or glibenclamide)

  • Nausea or dyspepsia

  • Dizziness or headache

Rare Adverse Effects:

  • Hepatic dysfunction

  • Hematologic reactions (e.g., agranulocytosis, thrombocytopenia)

  • Hypersensitivity or skin reactions

Contraindications

Gliclazide should be avoided in:

  • Type 1 diabetes

  • Diabetic ketoacidosis (DKA)

  • Severe renal or hepatic impairment

  • Pregnancy and lactation (insulin preferred)

  • Known hypersensitivity to sulfonylureas

Monitoring and Patient Education

To ensure safe and effective use of Gliclazide, monitoring and patient awareness are crucial:

Monitoring Parameters:

  • Blood glucose levels (FPG, PPG)

  • HbA1c every 3–6 months

  • Renal and hepatic function

  • Signs of hypoglycemia

Patient Education:

  • Importance of meal regularity to prevent hypoglycemia

  • Recognition and management of hypoglycemia

  • Lifestyle interventions: diet, exercise, and weight control

  • Avoiding alcohol (may potentiate hypoglycemia)

Special Populations

Elderly Patients:

Start with low doses due to increased hypoglycemia risk.

Renal Impairment:

Use with caution in mild-to-moderate impairment. Avoid in severe cases.

Pregnancy and Lactation:

Gliclazide is not recommended. Insulin therapy is preferred.

Gliclazide vs. Other Antidiabetic Drugs

Drug Class Hypoglycemia Risk Weight Impact Cardiovascular Safety
Gliclazide Sulfonylurea Low-moderate Mild gain Neutral/beneficial
Glibenclamide Sulfonylurea High Moderate gain Questionable
Metformin Biguanide Minimal Weight loss Beneficial
Sitagliptin DPP-4 inhibitor Minimal Neutral Neutral
Empagliflozin SGLT2 inhibitor Minimal Weight loss Cardioprotective

Role in Current Guidelines

Gliclazide remains a second-line option in most international guidelines (ADA, EASD, IDF) after Metformin, especially when cost, accessibility, or tolerability limit the use of newer agents.

It is also commonly prescribed in low- and middle-income countries due to its affordability and proven efficacy.

Fixed-Dose Combinations with Gliclazide

Gliclazide is available in fixed-dose combinations with:

  • Metformin

  • Pioglitazone

  • DPP-4 inhibitors (in some regions)

These combinations simplify regimens and improve adherence.

Future Outlook

As newer classes of antidiabetic drugs gain popularity, Gliclazide continues to hold a key place, especially for:

  • Cost-sensitive populations

  • Patients with contraindications to newer agents

  • Individuals at risk of microvascular complications

Ongoing research into personalized diabetes management may further refine Gliclazide’s role based on genetic profiles and beta-cell function.

Conclusion

Gliclazide remains a cornerstone in the pharmacological treatment of type 2 diabetes mellitus, offering a balance of efficacy, safety, and affordability. Its favorable profile—especially in terms of hypoglycemia risk and cardiovascular neutrality—makes it a preferred sulfonylurea for millions of patients globally. While newer therapies are available, Gliclazide’s evidence-based legacy and real-world effectiveness ensure its continued relevance in both monotherapy and combination regimens. With proper patient education and monitoring, Gliclazide can contribute meaningfully to the comprehensive care of diabetes.